The trial showed that the vaccine is well tolerated and that it has no safety issues, the company said. According to AstraZeneca, an independent committee found no increased risk of thrombosis or thrombotic events among the 21,583 participants who received at least one dose of the vaccine.
The new data comes from a Phase 3 clinical trial conducted in the US, Chile and Peru. AstraZeneca says it intends to submit the findings to a scientific journal for peer review.
In turn, Oxford said the findings ‘add to previous trial data from the UK, Brazil and South Africa, as well as the actual impact data from the UK’, according to a university press release.
As part of the trial, more than 32,000 volunteers recruited at all ages received two doses of the vaccine or a placebo vaccine with an interval of four weeks.
An emergency investigation by the European Medicines Agency (EMA) concluded last Thursday that the vaccine is ‘safe and effective’ in preventing coronavirus and ‘not associated with an increase in the overall risk of thromboembolic events’. , or blood clots. ‘
The vaccine’s co-designer and Oxford University professor of vaccination, Sarah Gilbert, praised the data for further confirmation of the vaccine’s safety and efficacy.
Chief vaccine researcher and professor of pediatric infection and immunity at the University of Oxford, Andrew Pollard, said the data from AstraZeneca “matched the results of Oxford-led trials”, adding that he had a “strong impact on COVID-19 in all ages and for people of all different backgrounds from the widespread use of the vaccine. “